Pedro Rodriguez, MD
Psychiatry · Miami, FLNPI 1386710572
Payments from drug & device makers
Across 905 payments — averaging $106.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$64K
- Otsuka America Pharmaceutical, Inc.$17K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$3K
- Johnson & Johnson$3K
- Vanda Pharmaceuticals Inc.$2K
- Lundbeck LLC$2K
- plus $6K from 19 others
What the payments were for
- Speaking & faculty fees$76,49780%
- Travel & lodging$2830%
- Food & beverage$19,20020%
- Education$1590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 251 | $63,870 |
| Otsuka America Pharmaceutical, Inc. | 143 | $16,994 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 69 | $3,064 |
| Johnson & Johnson | 10 | $2,749 |
| Vanda Pharmaceuticals Inc. | 80 | $2,016 |
| Lundbeck LLC | 67 | $1,519 |
| Takeda Pharmaceuticals U.S.A., Inc. | 64 | $1,105 |
| Teva Pharmaceuticals USA, Inc. | 34 | $876 |
| Bausch Health US, LLC | 40 | $760 |
| Alkermes, Inc. | 36 | $722 |
| Axsome Therapeutics, Inc. | 25 | $675 |
| Sunovion Pharmaceuticals Inc. | 29 | $506 |
| Tris Pharma Inc | 14 | $278 |
| E.r. Squibb & Sons, L.L.C. | 10 | $238 |
| Almatica Pharma LLC | 7 | $189 |
| Corium, LLC | 7 | $168 |
| Adlon Therapeutics L.p. | 5 | $103 |
| Indivior Inc. | 3 | $68 |
| Shire North American Group Inc | 3 | $60 |
| Neurocrine Biosciences, Inc. | 2 | $58 |
| Acadia Pharmaceuticals Inc | 2 | $42 |
| Noven Therapeutics, LLC | 1 | $23 |
| Ironshore Pharmaceuticals Inc. | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| Novo Nordisk | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$96,139 in reported general payments places this provider in the 90th percentile of 2,059 psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 141 | $218,496 |
| AustedoDeutetrabenazine | 14 | $164,989 |
| AtivanLorazepam | 15 | $101,572 |
| RexultiBrexpiprazole | 44 | $68,851 |
| Lurasidone Hcl | 60 | $47,579 |
| LybalviOlanzapine/Samidorphan Malate | 28 | $44,710 |
| CaplytaLumateperone Tosylate | 11 | $34,439 |
| Abilify MaintenaAripiprazole | 12 | $33,193 |
| NamzaricMemantine Hcl/Donepezil Hcl | 37 | $26,687 |
| TrintellixVortioxetine Hydrobromide | 50 | $24,307 |
| FanaptIloperidone | 21 | $22,592 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 87 | $19,090 |
| Aripiprazole | 134 | $16,723 |
| Chlorpromazine Hcl | 26 | $8,453 |
| Quetiapine Fumarate | 417 | $8,021 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Namzaric | $63,870 | $245,184178 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $876 | $164,98914 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $16,994 | $102,04456 claims |
| Alkermes, Inc.Lybalvi | $722 | $44,71028 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $3,064 | $34,43911 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $1,105 | $28,89762 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $2,016 | $22,59221 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,059 psychiatry providers in Florida.
Other psychiatry in Miami
- Silvia Silva-DulucMiami$11.7M
- Patricia JunqueraMiami$10.8M
- Evelio SosaMiami$6.9M
- Mario CuervoMiami$6.7M
- Emelina ArochaMiami$4.9M
- Maria RodilMiami$4.5M
- Marc AgroninMiami$4M
- Nancy Navarro-GonzalezMiami$2.6M
- Francisco RicartMiami$2.6M
- Durim BozhdarajMiami$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.